Pharma Journalist -

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

Biogen Inc. has announced that the U.S. Food and Drug Administration has approved a high-dose regimen of its therapy SPINRAZA for the treatment of spinal muscular atrophy (SMA), marking…
Read More...

The 5th In Vivo Cell Engineering & Gene Editing Summit returns to Boston this July, bringing together the scientific, translational, regulatory, and corporate leaders driving one of…
Read More...

Otsuka Pharmaceutical has announced plans to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, strengthening its presence in the neuropsychiatric treatment space…
Read More...

Corcept Therapeutics has announced that the U.S. Food and Drug Administration has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with…
Read More...

Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate the clinical development of antibody-drug conjugates (ADCs) in oncology, highlighting the growing…
Read More...

Cognito Therapeutics has partnered with Ochsner Health to establish a new Brain Health Collaboratory aimed at advancing innovative approaches to treating cognitive decline and…
Read More...

Merck & Co.—known as MSD outside North America—has announced a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening…
Read More...

UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for…
Read More...

Japan’s Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous…
Read More...